Management of moderate to severe plaque psoriasis in pregnancy and lactation in the Era of biologics

Acta Dermatovenerologica Alpina, Pannonica et Adriatica

Volumn 23, Issue 2, 2014, Pages 27-31

  Mervic, Liljana ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; CYCLOSPORIN A; ETRETIN; INFLIXIMAB; LIVE VACCINE; METHOTREXATE; MUTAGENIC AGENT; TERATOGENIC AGENT; USTEKINUMAB;

ARTICLE; DISEASE SEVERITY; DRUG SAFETY; HUMAN; HUMIDIFIER; IMMUNOSUPPRESSIVE TREATMENT; LACTATION; PERINATAL DRUG EXPOSURE; PHOTOTHERAPY; POSTMARKETING SURVEILLANCE; PREGNANCY; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PSORIASIS VULGARIS; SYSTEMIC THERAPY; TOPICAL TREATMENT; ULTRAVIOLET B RADIATION; FEMALE; PREGNANCY COMPLICATIONS; PSORIASIS; SEVERITY OF ILLNESS INDEX;

BIOLOGICAL PRODUCTS; FEMALE; HUMANS; LACTATION; PREGNANCY; PREGNANCY COMPLICATIONS; PSORIASIS; SEVERITY OF ILLNESS INDEX;

EID: 84907261529     PISSN: 13184458     EISSN: None     Source Type: Journal    
DOI: 10.15570/actaapa.2014.7     Document Type: Article

References (55)

1. Nestle FO, Kaplan DH, Barker JN. Psoriasis. N Engl J Med 2009;361:496-509.
2. Reich C. The concept of psoriasis as a systemic inflammation: implications for disease management. JEADV. 2012;26(Suppl 2):3-11.
3. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1-10.
4. Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. JEADV. 2009;23 (Suppl. 2):5-70.
5. Horn EJ, Chambers CD, Menter A, Kimball AB. Pregnancy outcomes in psoriasis: why do we know so little? J Am Acad Dermatol. 2009;61:e5-8.
6. Lima X, Janakiraman V, Hughes M, Kimball A. The impact of psoriasis on pregnancy outcomes. J Invest Dermatol. 2012;132:85-91.
7. Yang YW, Chen CH, Chen YH, Lin HC. Psoriasis and pregnancy outcomes: a nationwide population-based study. J Am Acad Dermatol. 2011;64:71-7.
8. Murase JE, Chan KK, Garite TJ, Cooper DM, Weinstein GD. Hormonal effect on psoriasis in pregnancy and post partum. Arch Dermatol. 2005;141:601-6.
9. Raychaudhuri SP, Navare T, Gross J, Raychaudhuri SK. Clinical course of psoriasis during pregnancy. Int J Dermatol. 2003;42:518-20.
10. Yip L, McCluskey J, Sinclair R. Immunological aspects of pregnancy. Clin Dermatol. 2006:24:84-7.
11. Bae YS, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Young M, et al. Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012:67:459-77.
12. Addis A, Sharabi S, Bonati M. Risk classification systems for drug use during pregnancy: are they a reliable source of information? Drug Saf. 2000;23:245-53.
13. Babalola O, Strober BE. Management of psoriasis in pregnancy. Dermatol Ther. 2013;26:285-92.
14. Edmundson WF, Guy WB. Treatment of psoriasis with folic acid antagonists. AMA Arch Derm. 1958;78:200-3.
15. Hyoun SC, Obican SG, Scialli AR. Teratogen update: methotrexate. Birth Defects Res A Clin Mol Teratol. 2012;94:187-207.
16. Kozlowski RD, Steinbrunner JV, MacKenzie AH, Clough JD, Wilke WS, Segal AM. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med. 1990;88:589-92.
17. Nguyen C, Duhl AJ, Escallon CS, Blakemore KJ. Multiple anomalies in a fetus exposed to low-dose methotrexate in the first trimester. Obstet Gynecol. 2002; 99:599-602.
18. Lloyd ME, Carr M, McElhatton P, Hall GM, Hughes RA. The effects of methotrexate on pregnancy, fertility and lactation. Q J Med. 1999;92:551-63.
19. Beghin D, Cournot MP, Vauzelle C, Elefant E. Paternal exposure to methotrexate and pregnancy outcomes. J Rheumatol. 2011;38:628-32.
20. Johns DG, Rutherford LD, Leighton PC, Vogel CL. Secretion of methotrexate into human milk. Am J Obst Gynecol. 1972;112:978-80.
21. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:776-89.
22. Wong RL, Winslow CM, Cooper KD. The mechanisms of action of cyclosporin A in the treatment of psoriasis. Immunol Today. 1993;14:69-74.
23. Petri M. Immunosuppressive drug use in pregnancy. Autoimmunity. 2003;36:51-6.
24. Perales-Puchalt A, Vila Vives JM, Lopez Montes J, Diago Almela VJ, Perales AJ. Pregnancy outcomes after kidney transplantation-immunosuppressive therapy comparison. Matern Fetal Neonatal Med. 2012;25:1363-6.
25. Lamarque V, Leleu MF, Monka C, Krupp P. Analysis of 629 pregnancy outcomes in renal transplant recipients with Sandimmune. Transplant Proc. 1997;29:2480.
26. Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation. 2001;71:1051-5.
27. Moretti ME, Sgro M, Johnson DW, Sauve RS, Woolgar MJ, Taddio A, et al. Cyclosporine excretion into breast milk. Transplantation. 2003;75:2144-6.
28. Geiger JM, Baudin M, Saurat JH. Teratogenic risk with etretinate and acitretin treatment. Dermatology. 1994;189:109-16.
29. Rollman O, Pihl-Lundin I. Acitretin excretion into human breast milk. Acta Derm Venereol. 1990;70:487-90.
30. European Medicines Agency [Internet]. Available from: http://www.ema.europa.eu/ema/.
31. Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology. 2013;17. [Epub ahead of print].
32. Carter JD, Valeriano J, Vasey FB. Tumor necrosis factor alpha inhibition and VATER association: a causal relationship. J Rheumatol. 2006:33:1014-7.
33. Centers for Disease Control and Prevention. Update on overall prevalence of major birth defects - Atlanta, Georgia, 1978-2005. MMWR Morb Mortal Wkly Rep. 2008;57:1-5.
34. Verstappen SM, King Y, Watson KD, Symmons DP, Hyrich KL. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70:823-6.
35. Marchioni RM, Lichtenstein GR. Tumor necrosis factor-alpha inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol. 2013;19:2591-602.
36. Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol. 2013;108:1426-38.
37. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol. 2004;99:2385-92.
38. Johnson DL, et al. Pregnancy outcomes in women exposed to etanercept: the OTIS Autoimme Diseases in Pregnancy Project. Arthritis Rheum. 2008;58:Abstract 1387.
39. Chambers CD, et al. Pregnancy outcomes in women exposed to adalimumab for the treatment of rheumatoid arthritis. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 3):377.
40. Andrulonis R, Ferris LK. Treatment of severe psoriasis with ustekinumab during pregnancy. J Drugs Dermatol 2012;11:1240-1.
41. Simister NE. Placental transport of immunoglobulin G. Vaccine. 2003;21:3365-9.
42. Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012:985646.
43. Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol. 2009;104:228-33.
44. Zelinkova Z, de Haar C, de Ridder L, Pierik MJ, Kuipers EJ, Peppelenbosch MP, et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharm Ther. 2011;33:1053-8.
45. Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:286-92.
46. Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol. 2006;4:1255-8.
47. Martin PL, Sachs C, Imai N, Tsusaki H, Oneda S, Jiao Q, et al. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation. Birth Defects Res B Dev Reprod Toxicol. 2010;89:351-63.
48. Berthelsen BG, Fjeldsoe-Nielsen H, Christoffer T, Nielsen CT, Hellmut E. Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. Rheumatology. 2010;49:2225-7.
49. Murashima A, Watanabe N, Ozawa N, Saito H, Yamaguchi K. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant's serum. Ann Rheum Dis. 2009;68:1793-4.
50. Cheent K, Nolan J, Shariq S, Kiho L, Pal A, Arnold J. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis.2010;4:603-5.
51. Østensen M, Frauke Förger F. How safe are anti-rheumatic drugs during pregnancy? Curr Opin Pharmacol. 2013, 13:470-5.
52. Ben-Horin S, Yavzori M, Kopylov U, Picard O, Fudim E, Eliakim R, et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis. 2011;5:555-8.
53. Ben-Horin S, Yavzori M, Katz L, Picard O, Fudim E, Chowers Y, et al. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol. 2010;8:475-6.
54. Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation. Part II. Lactation. J Am Acad Dermatol. 2014;70:417e1-10.
55. Saougou I, Markatseli TE, Papagoras C, Kaltsonoudis E, Voulgari PV, Drosos AA. Fertility in male patients with seronegative spondyloarthropathies treated with infliximab. Joint Bone Spine. 2013;80:34-7.